NeurologyLive Friday 5 — February 19, 2021


Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Adjusting Seizure Action Plans With Age

Scott Perry, MD; Orrin Devinksy, MD; and Tracy Salazar, PhD, detail how seizure action plans change from pediatrics to adults and the need for adjustments in the fourth segment of this group discussion.

2: Survey Clarifies Key Psychosocial Issues, Symptoms for Young Patients With Narcolepsy

The study data revealed some of the more common and problematic symptoms, challenges, and comorbidities that persist for these individuals despite care.

3: Reassessing CP Diagnosis to Involve Child Neurologists: Bhooma Aravamuthan, MD, DPhil

The assistant professor of pediatric neurology at Washington University in St. Louis spoke to the results of a recent survey she and colleagues conducted around the diagnosis of cerebral palsy.

4: NeuroVoices: Marwan Sabbagh, MD, on Assessing a Cancer Drug in Alzheimer Disease

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

5: Areas of Need in Epilepsy Research: Barbara Jobst, MD

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

NeurologyLive Wants Your Feedback!

We kindly ask you to share 5 minutes of your time with us, in order to help us better craft our content to meet your needs and interests.

Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.